The FDA has approved the DNA-damaging agent in combination with immunotherapy for patients whose cancers have not progressed after first-line therapy. The U.S. Food and Drug Administration (FDA) has approved lurbinectedin (Zepzelca) in combination...
For September 2025, the editors of AACR's journals highlighted studies on cervical cancer screening, supercharging immunotherapy, and more.
US trial to look at impact of AI-assisted mammograms, and vitamin B12 may help curb chemotherapy-associated hand-foot syndrome.
The FDA has approved imlunestrant for certain patients with advanced ESR1-mutated breast cancer that has progressed following previous endocrine therapy. The U.S. Food and Drug Administration (FDA) has approved imlunestrant (Inluriyo) for the treatment...
Richard and Michelle Schlueter attended the Rally for Medical Research to advocate for NIH funding after budget cuts delayed his treatment.
The FDA approved pembrolizumab and berahyaluronidase alfa-pmph as an injectable therapy for multiple tumor types. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for subcutaneous (under the...
Researchers are helping advance ovarian cancer care with breakthroughs that are reshaping treatment and early detection approaches.
Cancer survivors profiled over the past 15 years in the AACR Cancer Progress Reports shared updates on their lives and the progress made against cancer.
Combination of targeted therapy and chemotherapy prolongs survival in lung cancer, and FDA approves a chemotherapy-releasing device to treat bladder cancer.
FDA expands selumetinib approval to include pediatric patients as young as 1 year with inoperable plexiform neurofibromas. The U.S. Food and Drug Administration (FDA) has approved selumetinib (Koselugo) granules and capsules for pediatric patients...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More